In this revelatory episode, Carmel Fisher interviews Mr Rob Etherington CEO of Clene, Inc., listed on NASDAQ as CLNN.

Clene, Inc., a clinical-stage biopharmaceutical company is dedicated to revolutionizing the treatment of neurodegenerative diseases to restore and protect neuronal health and function.

There is no-one else who is theorizing orally-ingestive nanotherapeutics that target cellular energy impairments, common to many diseases, including  ...